Dimerix LimitedASX: DXB

DMX-200 First 100 Patients Complete Phase 3 Trial Treatment

· Issued by Dimerix Limited via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

The trial continues to progress, with a high percentage of patients opting to participate in the Open Label Extension study, which will provide additional long-term safety and efficacy data. This achievement reduces execution risk associated with long-duration trial retention and treatment adherence, crucial for the study's success.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/dmx-200-first-100-patients-complete-phase-3-trial-treatment

Release

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. [email protected] For Immediate Release DMX-200 ACTION3 PHASE 3 TRIAL: FIRST 100 PATIENTS COMPLETE DOUBLE-BLIND...

Dimerix Limited on 6ix

Earlier from Dimerix

Later from Dimerix

All Dimerix news releases